Invesco Biotechnology & Genome ETF PBE

Medalist Rating as of | See Invesco Investment Hub

Morningstar’s Analysis PBE

Will PBE outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PBE

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 48.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Natera Inc

6.24 26M
Healthcare

Illumina Inc

6.13 26M
Healthcare

Biogen Inc

5.22 22M
Healthcare

Gilead Sciences Inc

5.16 22M
Healthcare

Amgen Inc

4.86 21M
Healthcare

Vertex Pharmaceuticals Inc

4.83 20M
Healthcare

Royalty Pharma PLC Class A

4.76 20M
Healthcare

Regeneron Pharmaceuticals Inc

4.57 19M
Healthcare

Moderna Inc

3.54 15M
Healthcare

Novavax Inc

3.17 13M
Healthcare

Sponsor Center